GlassScriptPhysician profile
Jennifer Moore
NPI 1508919358
$3,867.87
in general payments reported to CMS, 2019-2025
28 companies · $648 in 2025
The $648 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $583 · 2021: $769 · 2022: $524 · 2023: $669 · 2024: $284 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $681.23 | 2022-2025 | Azstarys |
| Tris Pharma INC | $654.80 | 2019-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $397.15 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $371.07 | 2019-2025 | |
| Neos Therapeutics, LP | $267.07 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $164.19 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $155.96 | 2020-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Adlon Therapeutics L.P. | $141.61 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $140.38 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $114.48 | 2019-2025 | Doc Band |
| Kaleo, INC. | $106.87 | 2019-2021 | |
| Glaxosmithkline, LLC. | $98.40 | 2019-2024 | Bexsero |
| Seqirus USA INC | $78.59 | 2021-2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $78.37 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $76.97 | 2025 | Daybue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.99 | 2025 | |
| Sanofi Pasteur INC. | $51.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.25 | 2022-2023 | Flumist Quadrivalent |
| Abbvie INC. | $26.56 | 2021-2022 | |
| Alk-Abello, INC | $23.88 | 2021 | |
| Sobi, INC | $21.54 | 2022 | |
| Abbott Laboratories | $18.11 | 2025 | Id Now Instrument |
| Rhodes Pharmaceuticals L.P. | $17.77 | 2019 | |
| Qiagen, LLC | $17.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.38 | 2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $15.34 | 2025 | Natroba, Spinosad |
| Alexion Pharmaceuticals, INC. | $14.56 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.